Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone: a multicentre, open-label, parallel-group, phase II-III, randomised superiority study (CAIRO6). - CAIRO6

Catharina-ziekenhuis0 个研究点目标入组 298 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

暂无简介。

•Eligible patients are adults who have:
•* a World Health Organisation (WHO) performance status of <=1;
•* histological or cytological proof of PM of a non-appendiceal colorectal
•adenocarcinoma with <=50% of the tumour cells being signet ring cells;
•* resectable disease determined by abdominal computed tomography (CT) and a
•diagnostic laparoscopy/laparotomy;
•* no evidence of systemic colorectal metastases within three months prior to
•* no systemic therapy for colorectal cancer within six months prior to
•* no contraindications for CRS-HIPEC;
•* no previous CRS-HIPEC;
•* no concurrent malignancies that interfere with the planned study treatment or
•the prognosis of resected colorectal PM.

•Patients are excluded in case of any comorbidity or condition that prevents
•safe administration of the planned perioperative systemic therapy, determined
•by the treating medical oncologist, e.g.:
•* Inadequate bone marrow, renal, or liver functions (e.g. haemoglobin <6.0
•mmol/L, neutrophils <1.5 x 109/L, platelets <100 x 109/L, serum creatinine >1.5
•x ULN, creatinine clearance <30 ml/min, bilirubin >2 x ULN, serum liver
•transaminases >5 x ULN);
•* Previous intolerance of fluoropyrimidines or both oxaliplatin and irinotecan;
•* Dehydropyrimidine dehydrogenase deficiency;
•* Serious active infections;
•* Severe diarrhoea;
•* Stomatitis or ulceration in the mouth or gastrointestinal tract;
•* Recent major cardiovascular events;
•* Unstable or uncompensated respiratory or cardiac disease;
•* Bleeding diathesis or coagulopathy;
•* Pregnancy or lactation.

发起方